RECURRENT MYELODYSPLASTIC SYNDROME

This study tests a specific schedule of chemotherapy drugs (busulfan and fludarabine) followed by a donor stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. After the transplant, a drug called cyclophosphamide is given to help prevent the don…

This study tests a new drug (seclidemstat) combined with a standard drug (azacitidine) for people with myelodysplastic syndromes or chronic myelomonocytic leukemia. The goal is to find the best dose and see if the combo can shrink or control the cancer. About 24 adults with these…

This early-stage trial tested whether adding regorafenib to the standard venetoclax and azacitidine regimen is safe and effective for adults with acute myeloid leukemia (AML) that has returned or not responded to prior treatment. The study aimed to find the best dose and check fo…

This study tests a combination of two drugs, venetoclax and azacitidine, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) that has returned or not responded to standard therapy. The goal is to find the best dose and see how well th…

This early-stage trial tests a new drug called TAK-243 in about 42 adults whose acute myeloid leukemia or myelodysplastic syndrome has returned or stopped responding to standard therapy. The main goals are to find the best dose and check for side effects. TAK-243 works by blockin…

This early-stage trial tests a new drug called DR-18 in 20 adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has come back or persists after a stem cell transplant. DR-18 is designed to boost the body's immune system to fight the cancer. The main goals a…

This study tests a combination of two drugs, azacitidine and quizartinib, in 30 adults with certain blood cancers (MDS, MDS/MPN, CMML) that have specific gene mutations (FLT3 or CBL). The goal is to find the best dose and see how well the drugs control the cancer. This is not a c…

This study tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus a chemotherapy drug (azacitidine) in people with myelodysplastic syndromes (MDS), a bone marrow disorder that can lead to leukemia. About 99 adults with MDS, either untreated or who have fai…

This study tests a drug called olaparib in 14 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or not responded to treatment, and who have a specific change in the IDH gene. The drug works by blocking enzymes that cancer cells need to g…

This early-stage study tests a combination of two drugs—ipilimumab, which boosts the immune system to attack cancer, and decitabine, a chemotherapy drug—in people whose myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) has returned or not responded to prior treatment…

This early-phase trial tests a new drug called uproleselan combined with standard chemotherapy (fludarabine and cytarabine) in children and teens with acute myeloid leukemia, myelodysplastic syndrome, or mixed phenotype acute leukemia that has returned or not responded to treatme…